L-kynurenine/aryl hydrocarbon receptor pathway mediates brain damage after experimental stroke

Circulation

Volumn 130, Issue 23, 2014, Pages 2040-2051

  Cuartero, María I ^a   Ballesteros, Iván ^a   De La Parra, Juan ^a   Harkin, Andrew L ^b   Abautret Daly, Aine ^b   Sherwin, Eoin ^b   Fernández Salguero, Pedro ^c   Corbí, Ángel L ^d   Lizasoain, Ignacio ^a   Moro, María A ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c UNIVERSITY OF EXTREMADURA   (Spain)

^d CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

Aryl hydrocarbon receptor; L kynurenine; Stroke

Indexed keywords

6,2',4' TRIMETHOXYFLAVONE 14; AROMATIC HYDROCARBON RECEPTOR; BENZO[A]PYRENE; BRAIN DERIVED NEUROTROPHIC FACTOR; CASPASE 3; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; DNA NUCLEOTIDYLEXOTRANSFERASE; FLAVONE DERIVATIVE; KYNURENINE; LACTATE DEHYDROGENASE; MESSENGER RNA; UNCLASSIFIED DRUG; 2-METHYL-2H-PYRAZOLE-3-CARBOXYLIC ACID (2-METHYL-4-O-TOLYLAZOPHENYL)AMIDE; 6,2',4'-TRIMETHOXYFLAVONE; AHR PROTEIN, MOUSE; AHR PROTEIN, RAT; AZO COMPOUND; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; PYRAZOLE DERIVATIVE;

AMINO ACID SYNTHESIS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; BRAIN DAMAGE; BRAIN INFARCTION SIZE; CELL NUCLEUS; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CYTOPLASM; EXPERIMENTAL STROKE; GENETIC TRANSCRIPTION; GENOTYPE; HYDROGEN BOND; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; LOSS OF FUNCTION MUTATION; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROPROTECTION; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; BRAIN ISCHEMIA; C57BL MOUSE; CEREBRAL ARTERY DISEASE; CYTOLOGY; DISEASE MODEL; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM; NERVE CELL; PATHOLOGY; PHYSIOLOGY; PRIMARY CELL CULTURE; TRANSCRIPTION INITIATION; YOUNG ADULT;

ANIMALS; AZO COMPOUNDS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BRAIN; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; FLAVONES; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; KYNURENINE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEURONS; PRIMARY CELL CULTURE; PYRAZOLES; RECEPTORS, ARYL HYDROCARBON; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; YOUNG ADULT;

EID: 84916936785     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.114.011394     Document Type: Article

References (44)

1. Fonarow GC, Smith EE, Saver JL, Reeves MJ, Bhatt DL, Grau-Sepulveda MV, Olson DM, Hernandez AF, Peterson ED, Schwamm LH. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: Patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation. 2011;123: 750-758.
2. Raimo P. The Ah Receptor in Biology and Toxicology. New York, NY: John Wiley and Sons; 2012.
3. Nguyen LP, Bradfield CA. The search for endogenous activators of the aryl hydrocarbon receptor. Chem Res Toxicol. 2008;21: 102-116.
4. Furness SG, Whelan F. The pleiotropy of dioxin toxicity-xenobiotic misappropriation of the aryl hydrocarbon receptor's alternative physiological roles. Pharmacol Ther. 2009;124: 336-353.
5. Fernandez-Salguero PM, Ward JM, Sundberg JP, Gonzalez FJ. Lesions of aryl-hydrocarbon receptor-deficient mice. Vet Pathol. 1997;34: 605-614.
6. Sauzeau V, Carvajal-González JM, Riolobos AS, Sevilla MA, Menacho-Márquez M, Román AC, Abad A, Montero MJ, Fernández-Salguero P, Bustelo XR. Transcriptional factor aryl hydrocarbon receptor (Ahr) controls cardiovascular and respiratory functions by regulating the expression of the Vav3 proto-oncogene. J Biol Chem. 2011;286: 2896-2909.
7. Quintana FJ, Sherr DH. Aryl hydrocarbon receptor control of adaptive immunity. Pharmacol Rev. 2013;65: 1148-1161.
8. Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, Jugold M, Guillemin GJ, Miller CL, Lutz C, Radlwimmer B, Lehmann I, von Deimling A, Wick W, Platten M. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature. 2011;478: 197-203.
9. Gohlke JM, Stockton PS, Sieber S, Foley J, Portier CJ. AhR-mediated gene expression in the developing mouse telencephalon. Reprod Toxicol. 2009;28: 321-328.
10. Hays LE, Carpenter CD, Petersen SL. Evidence that GABAergic neurons in the preoptic area of the rat brain are targets of 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin during development. Environ Health Perspect. 2002;110(suppl 3): 369-376.
11. Williamson MA, Gasiewicz TA, Opanashuk LA. Aryl hydrocarbon receptor expression and activity in cerebellar granule neuroblasts: Implications for development and dioxin neurotoxicity. Toxicol Sci. 2005;83: 340-348.
12. Lin CH, Chen CC, Chou CM, Wang CY, Hung CC, Chen JY, Chang HW, Chen YC, Yeh GC, Lee YH. Knockdown of the aryl hydrocarbon receptor attenuates excitotoxicity and enhances NMDA-induced BDNF expression in cortical neurons. J Neurochem. 2009;111: 777-789.
13. Lin CH, Juan SH, Wang CY, Sun YY, Chou CM, Chang SF, Hu SY, Lee WS, Lee YH. Neuronal activity enhances aryl hydrocarbon receptormediated gene expression and dioxin neurotoxicity in cortical neurons. J Neurochem. 2008;104: 1415-1429.
14. Murray IA, Flaveny CA, DiNatale BC, Chairo CR, Schroeder JC, Kusnadi A, Perdew GH. Antagonism of aryl hydrocarbon receptor signaling by 6, 2', 4'-trimethoxyflavone. J Pharmacol Exp Ther. 2010;332: 135-144.
15. Zhao B, Degroot DE, Hayashi A, He G, Denison MS. CH223191 is a ligandselective antagonist of the Ah (dioxin) receptor. Toxicol Sci. 2010;117: 393-403.
16. Kawasaki H, Chang HW, Tseng HC, Hsu SC, Yang SJ, Hung CH, Zhou Y, Huang SK. A tryptophan metabolite, kynurenine, promotes mast cell activation through aryl hydrocarbon receptor. Allergy. 2014;69: 445-452.
17. Nguyen NT, Kimura A, Nakahama T, Chinen I, Masuda K, Nohara K, Fujii-Kuriyama Y, Kishimoto T. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc Natl Acad Sci U S A. 2010;107: 19961-19966.
18. Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol. 2010;185: 3190-3198.
19. Fernandez-Salguero P, Pineau T, Hilbert DM, McPhail T, Lee SS, Kimura S, Nebert DW, Rudikoff S, Ward JM, Gonzalez FJ. Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. Science. 1995;268: 722-726.
20. Davarinos NA, Pollenz RS. Aryl hydrocarbon receptor imported into the nucleus following ligand binding is rapidly degraded via the cytosplasmic proteasome following nuclear export. J Biol Chem. 1999;274: 28708-28715.
21. Lonze BE, Riccio A, Cohen S, Ginty DD. Apoptosis, axonal growth defects, and degeneration of peripheral neurons in mice lacking CREB. Neuron. 2002;34: 371-385.
22. Mantamadiotis T, Lemberger T, Bleckmann SC, Kern H, Kretz O, Martin Villalba A, Tronche F, Kellendonk C, Gau D, Kapfhammer J, Otto C, Schmid W, Schütz G. Disruption of CREB function in brain leads to neurodegeneration. Nat Genet. 2002;31: 47-54.
23. Finkbeiner S. CREB couples neurotrophin signals to survival messages. Neuron. 2000;25: 11-14.
24. Darlington LG, Mackay GM, Forrest CM, Stoy N, George C, Stone TW. Altered kynurenine metabolism correlates with infarct volume in stroke. Eur J Neurosci. 2007;26: 2211-2221.
25. Vécsei L, Szalárdy L, Fülöp F, Toldi J. Kynurenines in the CNS: Recent advances and new questions. Nat Rev Drug Discov. 2013;12: 64-82.
26. Barouki R, Coumoul X, Fernandez-Salguero PM. The aryl hydrocarbon receptor, more than a xenobiotic-interacting protein. FEBS Lett. 2007;581: 3608-3615.
27. Sánchez-Martín FJ, Fernández-Salguero PM, Merino JM. Aryl hydrocarbon receptor-dependent induction of apoptosis by 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin in cerebellar granule cells from mouse. J Neurochem. 2011;118: 153-162.
28. Kajta M, Wójtowicz AK, Mackowiak M, Lason W. Aryl hydrocarbon receptor-mediated apoptosis of neuronal cells: A possible interaction with estrogen receptor signaling. Neuroscience. 2009;158: 811-822.
29. Schäbitz WR, Sommer C, Zoder W, Kiessling M, Schwaninger M, Schwab S. Intravenous brain-derived neurotrophic factor reduces infarct size and counterregulates Bax and Bcl-2 expression after temporary focal cerebral ischemia. Stroke. 2000;31: 2212-2217.
30. Schäbitz WR, Schwab S, Spranger M, Hacke W. Intraventricular brainderived neurotrophic factor reduces infarct size after focal cerebral ischemia in rats. J Cereb Blood Flow Metab. 1997;17: 500-506.
31. Endres M, Fan G, Hirt L, Fujii M, Matsushita K, Liu X, Jaenisch R, Moskowitz MA. Ischemic brain damage in mice after selectively modifying BDNF or NT4 gene expression. J Cereb Blood Flow Metab. 2000;20: 139-144.
32. Stone TW, Forrest CM, Stoy N, Darlington LG. Involvement of kynurenines in Huntington's disease and stroke-induced brain damage. J Neural Transm. 2012;119: 261-274.
33. Gál EM, Sherman AD. Synthesis and metabolism of L-kynurenine in rat brain. J Neurochem. 1978;30: 607-613.
34. Kanai M, Funakoshi H, Takahashi H, Hayakawa T, Mizuno S, Matsumoto K, Nakamura T. Tryptophan 2, 3-dioxygenase is a key modulator of physiological neurogenesis and anxiety-related behavior in mice. Mol Brain. 2009;2: 8.
35. Kanai M, Nakamura T, Funakoshi H. Identification and characterization of novel variants of the tryptophan 2, 3-dioxygenase gene: Differential regulation in the mouse nervous system during development. Neurosci Res. 2009;64: 111-117.
36. Wu W, Nicolazzo JA, Wen L, Chung R, Stankovic R, Bao SS, Lim CK, Brew BJ, Cullen KM, Guillemin GJ. Expression of tryptophan 2, 3-dioxygenase and production of kynurenine pathway metabolites in triple transgenic mice and human Alzheimer's disease brain. PLoS One. 2013;8: E59749.
37. Dale WE, Dang Y, Brown OR. Tryptophan metabolism through the kynurenine pathway in rat brain and liver slices. Free Radic Biol Med. 2000;29: 191-198.
38. Green AR, Woods HF, Joseph MH. Tryptophan metabolism in the isolated perfused liver of the rat: Effects of tryptophan concentration, hydrocortisone and allopurinol on tryptophan pyrrolase activity and kynurenine formation. Br J Pharmacol. 1976;57: 103-114.
39. Guillemin GJ, Smythe G, Takikawa O, Brew BJ. Expression of indoleamine 2, 3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia. 2005;49: 15-23.
40. Nozaki K, Beal MF. Neuroprotective effects of L-kynurenine on hypoxiaischemia and NMDA lesions in neonatal rats. J Cereb Blood Flow Metab. 1992;12: 400-407.
41. Vécsei L, Miller J, MacGarvey U, Beal MF. Kynurenine and probenecid inhibit pentylenetetrazol-and NMDLA-induced seizures and increase kynurenic acid concentrations in the brain. Brain Res Bull. 1992;28: 233-238.
42. Gigler G, Szénási G, Simó A, Lévay G, Hársing LG Jr, Sas K, Vécsei L, Toldi J. Neuroprotective effect of L-kynurenine sulfate administered before focal cerebral ischemia in mice and global cerebral ischemia in gerbils. Eur J Pharmacol. 2007;564: 116-122.
43. Robotka H, Sas K, Agoston M, Rózsa E, Szénási G, Gigler G, Vécsei L, Toldi J. Neuroprotection achieved in the ischaemic rat cortex with L-kynurenine sulphate. Life Sci. 2008;82: 915-919.
44. Gellért L, Knapp L, Németh K, Herédi J, Varga D, Oláh G, Kocsis K, Menyhárt A, Kis Z, Farkas T, Vécsei L, Toldi J. Post-ischemic treatment with L-kynurenine sulfate exacerbates neuronal damage after transient middle cerebral artery occlusion. Neuroscience. 2013;247: 95-101.